Association between Dietary Inflammatory Index and serum Klotho concentration among adults in the United States

Chichen Zhang1†, Zilong Zhang1†, Jiakun Li1†, Linghui Deng2,3, Jiwen Geng4, Kun Jin1, Xiaonan Zheng1, Shi Qiu1* and BiRong Dong2,3*

Abstract

Background: Klotho is a hormone that emerges as an antiaging biomarker. However, the influence of the dietary pattern's inflammatory potential on serum Klotho levels in human populations, especially in a general adult population, remains unknown. This study aimed to evaluate the relationship between the dietary inflammatory index (DII) and serum Klotho concentrations in individuals living in the United States.

Methods: From the 2007–2016 National Health and Nutrition Examination Survey database, data of participants who completed the full 24-h dietary history and underwent serum Klotho testing were analyzed. The association between DII and serum Klotho concentrations was estimated using multivariable linear regression models. We also conducted segmented regression model to examine the threshold effect of DII on serum Klotho concentrations.

Results: A total of 10,928 participants were included, with a median serum Klotho concentration of 805.20 pg/mL (IQR: 657.58 – 1001.12) and a median DII of 1.43 (IQR: −0.16 – 2.82). Multivariable regression showed that participants with high DII scores were associated with low serum Klotho concentrations; when classifying DII into quartiles, after full adjustment, participants in DII quartiles 3 and 4 showed a decrease in Klotho levels (25.27 and 12.44 pg/ml, respectively) compared with those in the lowest quartile (quartile 1) (95% CI: −41.80, −8.73 and −29.83, 4.95, respectively; P for trend = 0.036). The segmented regression showed that the turning point value of DII was −1.82 (95% CI: −2.32, −0.80). A 1-unit increase in DII was significantly associated with lower Klotho levels by −33.05 (95% CI: −52.84, −13.27; P = 0.001) when DII ranges from −5.18 to −1.82; however, the relationship was not significant when DII ranges from −1.82 to 5.42 (P > 0.05). Furthermore, stratified analyses indicated that the observed associations between DII and serum Klotho concentration were stronger among those aged ≥ 56 years, those with normal weight, and those without chronic kidney disease (P for interaction = 0.003, 0.015, and 0.041, respectively).

†Chichen Zhang, Zilong Zhang and Jiakun Li contributed equally to this work.
*Correspondence: qiushi@scu.edu.cn; birongdong123@outlook.com
1 Department of Urology, Institute of Urology and National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, No. 37, Guoxue Lane, Chengdu 610041, Sichuan Province, People’s Republic of China
2 National Clinical Research Center of Geriatrics, The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, People’s Republic of China
Full list of author information is available at the end of the article
Introduction

Alpha-Klotho (Klotho) is a single-pass transmembrane protein encoded by the klotho gene. It is highly expressed in the distal convoluted tubules of the kidney and acts as an obligate coreceptor for fibroblast growth factor 23 (FGF23) [1, 2]. Kuro-o et al. first identified Klotho as a regulator of senescence in a mouse model with klotho gene expression defects resulting in multiple premature-aging syndromes and a short lifespan [1]. Conversely, the klotho gene also suppress aging in mammals, and its overexpression is related to an extended lifespan of up to 30% in transgenic mice [3]. Klotho has been emerged as an antiaging biomarker and functions as a hormone; it also participates in suppressing oxidative stress and inflammation [4]. Klotho deficiency is linked to numerous aging-related diseases, such as cancers, osteoporosis, cardiovascular and renal diseases, and neurodegenerative disorders [5-7]. Recently, low serum Klotho concentration was found to be associated with all-cause mortality in a nationally representative sample of American adults [8].

Currently, dietary patterns play an important role in life expectancy and reduce the risk of overall mortality and morbidity [9, 10]. Proinflammatory cytokine secretion, especially tumor necrosis factor-α (TNF-α), interferon γ (IFN-γ), and interleukin-6 (IL-6) [11], downregulates klotho gene expression [12]. Through histone acetylation, inflammatory cytokines could cause the epigenetic inactivation of Klotho transcription [13]. Diets high in fruits, vegetables, nuts, and whole grains are associated with decreased inflammation [14]. In a previous study, nut consumption was positively associated with serum Klotho levels [15]. Thus, a proinflammatory diet may reduce the level of serum Klotho, which is used as an indicator of klotho gene expression [4]; such reduction may accelerate aging. The Dietary Inflammatory Index (DII) is a recent developed standardized scoring system used to evaluate tools characterizing the inflammatory potential of a person's diet by using a quantitative scale from anti- to proinflammation [16]. It was validated in diverse populations to predict the levels of inflammatory markers such as C-reactive protein, TNF-α, and IL-6 [17-19]. In addition, DII was associated with a wide range of other inflammatory-related diseases, such as obesity, various cancers, cardiovascular diseases, and shortened telomere length [20-23]. However, studies that investigated the association between the DII and serum Klotho levels are scarce, and the results are inconsistent. Jurado-Fasoli et al. found that DII was positively associated with serum Klotho in middle-aged adults [24] but negatively associated in young sedentary healthy adults [25].

Therefore, the insight into whether the inflammatory potential of the dietary pattern could influence serum Klotho levels in human populations, especially in a general adult population, remains unknown. Therefore, this study aimed to evaluate the association between dietary inflammatory potential and serum Klotho concentrations in a nationally representative sample of adults in the United States. We hypothesized that individuals with a high proinflammatory diet would have a lower Klotho level than those with a high anti-inflammatory diet.

Material and method

Sample population

The National Health and Nutrition Examination Survey (NHANES) is a major ongoing program of the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention. NHANES is designed to assess the health and nutritional status of noninstitutionalized residents in the United States. It uses a complex, stratified, multistage, probability sampling design to identify participants representative of the target population. It is unique in such a way that it not only collects questionnaire data through in-person interviews but also...
performs health examinations in a mobile examination center and collects specimens for laboratory tests. More details about NHANES can be found on their website (https://www.cdc.gov/nchs/nhanes/about_nhanes.htm). This study obtained written informed consent in all participants and was approved by the NCHS Ethics Review Board.

In this study, we limited individual data to five continuous NHANES cycles: 2007–2008, 2009–2010, 2011–2012, 2013–2014, and 2015–2016 (50,588 in total). Serum klotho was only measured among those aged 40–79 years who consented to surplus serum collection for future research. Thus, participants who completed the full 24-h dietary history and underwent serum Klotho testing were included. We excluded those with incomplete data on dietary recall assessments (n = 6,600) and serum klotho (n = 31,027). We also excluded participants who were diagnosed with cancer or stroke. Ultimately, 10,928 participants were included in the final analyses (Supplementary Fig. 1).

Assessment of dietary inflammatory index
Dietary intake information was collected in NHANES using 24-h dietary recall interviews conducted at the Mobile Examination Center. The Food Surveys Research Group of the US Department of Agriculture is responsible for the methodology of dietary data collection, maintenance of the databases used to code and process the data, and data review and processing. Shivappa N et al. reported the development and validation of the DII [16, 18]. DII scores were generated using the first 24-h dietary information was used to generate DII scores [16]. In this study, 27 of 45 food parameters were available through the NHANES database, including protein; fat; alcohol; carbohydrates; fiber; cholesterol; omega-3 and omega-6 polyunsaturated fatty acids; saturated, monounsaturated, and polyunsaturated fatty acids; niacin; vitamins A, B1, B2, B6, B12, C, D, and E; iron; magnesium; zinc; selenium; folic acid; beta carotene; and caffeine. Each parameter labeled with an inflammatory effect score and the methodology of calculating DII are described in detail in Supplementary Material. The DII scores’ calculation was based on the intake of each food component as expressed per 1000 cal food consumed, also known as the energy-adjusted dietary inflammatory index (E-DII) [26]. In total, the DII score reflects the properties of the participant’s dietary intake from anti-inflammation (low DII scores) to proinflammation (high DII scores) [16].

Serum Klotho concentration
Serum specimens were stored at -80 °C at the Centers for Disease Control and Prevention in Atlanta, GA. They were shipped on dry ice to the Northwest Lipid Metabolism and Diabetes Research Laboratories at the University of Washington in Seattle, WA, during the period 2019–2020. Klotho concentrations were determined on frozen NHANES 2007–2016 samples that were tested through a commercially available ELISA kit produced by IBL International, Japan [27]. All samples were analyzed twice, and the final value was calculated using the average of the two concentrations. Two quality control samples, including low and high Klotho concentrations, were also analyzed twice in each plate. The analysis results were automatically transmitted from the instrument to the laboratory Oracle Management System for the area supervisor to evaluate. Samples with duplicate values exceeding 10% were flagged to be retested. If the value of a quality control sample was not within two standard deviations (SDs) of the assigned value, the sample analysis was repeated. The assay sensitivity was 6 pg/mL, and all the final values of the samples exceeded this limitation, so no imputation was performed.

Study covariates
Potential confounders were selected a priori according to a literature review [23, 28, 29]. Sociodemographic characteristics such as age, sex, self-reported race/ethnicity (Mexican American, Other Hispanic, non-Hispanic White, non-Hispanic Black, or other race), family income/poverty ratio, body mass index (BMI), physical activity, smoking status, alcohol intake, and estimated glomerular filtration rate (eGFR) were assessed. BMI was calculated according to self-reported weight and height measurements and was categorized into <25, 25–29.9, or ≥30 kg/m². Physical activity was classified into less than moderate (0 min/week moderate-to-vigorous physical activity [MVPA]), moderate active (<150 min/week MVPA), and vigorous active (≥150 min/week MVPA) [30]. In accordance with the NCHS classifications, individuals were categorized into never, former, and current smokers [31]. Alcohol intake was categorized as none (0 g/d), moderate (male: 0.1 to 27.9 g/d, female: 0.1 to 13.9 g/d), and heavy drinking (male: ≥28 g/d, female: ≥14 g/d) [31]. Furthermore, the participants’ kidney function was evaluated by measuring the eGFR using the new Chronic Kidney Disease Epidemiology Collaboration Eq. [32]. The urinary albumin/creatinine ratio (ACR) was also calculated. According to the extended definition of chronic kidney disease (CKD), participants with an ACR ≥30 mg/g or an eGFR ≤60 ml/min/1.73m² had CKD [28].

Statistical analyses
We used the appropriate survey procedures to account for the complex sampling design and weights in NHANES (https://www.cdc.gov/nchs/nhanes/analy
ticguidelines.aspx). Continuous variables are presented as the mean±SD or median and interquartile range (IQR) when appropriate, whereas categorical variables are expressed as percentages. The differences between the DII quartile groups were compared using the Student’s-t test or Mann–Whitney U test for the continuous variables and the chi-square or Fisher’s exact test for the categorical variables.

The association between DII and serum Klotho concentrations was estimated using multivariable linear regression models including the nonadjusted model (model 1), minimally adjusted model II (only age, sex, and race were adjusted), and fully adjusted model III (age, sex, race, family income/poverty ratio, BMI, alcohol intake, physical activity, smoking status, and eGFR were adjusted). DII was treated as both a continuous independent variable and a categorical variable (divided into quartiles), with the lowest quartile used as the reference. Linear trend tests were performed by entering the median value of each DII category as a continuous variable in the models. We further applied smooth curve fitting and segmented regression (also known as piece-wise regression) model to examine the threshold effect of DII on serum Klotho concentrations. Log-likelihood ratio test that compares one-line (non-segmented) model with segmented regression model was also conducted. To explore whether the association was modified by age, sex, BMI, physical activity, and CKD, we conducted interaction analyses and stratified analyses. Moreover, the effects of outliers (serum Klotho and DII) on our results were assessed by sensitivity analysis. We tested the stability of our results after excluding those with Klotho levels >2500 pg/ml, those with Klotho levels >2000 pg/ml, and those with Klotho levels >2000 pg/ml and DII >5.

All statistical data were analyzed using the software packages R (http://www.R-project.org, The R Foundation) and Empower (R www.empowerstats.com; X&Y Solutions, Inc., Boston, MA). A two-tailed P value < 0.05 was considered statistically significant.

Results
Table 1 shows the population characteristics and sorted by DII quartiles. Overall, 10,928 participants were included, with a median age of 56.00 (47.00–65.00) years, and 48.54% were males. The median DII was 1.43 (−0.16–2.82), ranging from −5.18 to 5.42. The median serum Klotho concentration was 805.20 (657.58–1001.12) pg/ml. The median eGFR was 90.80 (76.29–102.37) ml/min/1.73m², and 18.26% of the participants had CKD. Serum Klotho concentrations were similar between the DII quartile groups. Participants in the highest DII group were more likely to be older, female, non-Hispanic black, and obese, have never smoked, have a lower eGFR, have a PIR <1.3, and have less than moderate physical activity than those in the lowest DII group (all P<0.05).

Table 2 presents the associations between DII and serum Klotho concentration. Participants with a higher DII score were associated with a lower serum Klotho concentration. After minimal and full adjustment, a 1-unit increase in DII was significantly associated with lower Klotho levels by 4.52 and 4.39 pg/ml in models 2 and 3, respectively (model 2: 95% CI: −7.39, −1.65, P=0.002; model 3: 95% CI: −7.49, −1.28, P=0.006). Moreover, the significant association persisted when classifying DII into quartiles. After adjustment for age, sex, and race, the DII was negatively associated with serum Klotho concentration (P for trend=0.015). Compared with those at quartile 1, those at quartiles 2 and 3 had significantly decreased klotho levels (15.17 and 32.62 pg/ml) (95% CI: −30.29, −0.04; P=0.049; 95% CI: −48.30, −16.95; P<0.001, respectively). In the fully adjusted model, participants in the highest DII quartile had a 12.44 pg/ml decrease in Klotho levels compared with those in the lowest quartile (P for trend=0.036; 95% CI: −29.83, 4.95; P=0.161). Additionally, the β values for serum Klotho concentration among participants in DII quartiles 2 and 3 were 9.75 and 25.27 pg/ml, respectively, compared with those in the lowest quartile. (95% CI: −25.53, 6.03, P=0.226; 95% CI: −41.80, −8.73, P=0.003, respectively). A nonlinear relationship between DII and serum Klotho concentrations was observed by smoothing curve fitting after fully adjustment. (Supplementary Fig. 2) The segmented regression showed that the turning point value of DII was −1.82 (95% CI: −2.32, −0.80). A 1-unit increase in DII was significantly associated with lower Klotho levels by −33.05 (95% CI: −52.84, −13.27; P=0.001) when DII ranges from −5.18 to −1.82; however, the relationship was not significant when DII ranges from −1.82 to 5.42 (P>0.05). (Log likelihood ratio test: 0.004; Table 3) In sensitivity analysis, the significant association persisted after excluding participants with Klotho levels >2500 pg/ml, those with Klotho levels >2000 pg/ml, and those with Klotho levels >2000 pg/ml and DII >5, respectively (data not shown).

In stratified analyses, the observed associations between DII and serum Klotho concentration were stronger among those aged ≥56 years, normal weight, and without CKD. (P for interaction=0.003, 0.015, and 0.041, respectively) (Table 4). When we limited the analysis to individuals aged ≥56 years, participants within DII quartile 2, 3, and 4 were associated with a 30.10, 45.72, and 32.21 pg/ml Klotho level decrease when compared with DII quartile 1 (95% CI: −49.18, −11.02; −65.20, −26.24; −52.61, −11.81, respectively; P for trend<0.001). A 1-unit increase in the DII was also associated with lower serum Klotho
Table 1  Characteristics of participants in the 2007–2016 NHANES

| Characteristic          | Total     | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P value |
|-------------------------|-----------|------------|------------|------------|------------|---------|
| Number                  | 10,928    | 2732       | 2732       | 2732       | 2732       |         |
| DII (median, IQR)       | 1.43 (-0.16–2.82) | -1.24 (-2.06–0.67) | 0.69 (0.28–1.08) | 2.13 (1.79–2.48) | 3.57 (3.17–4.08) | < 0.001 |
| Age (median, IQR), years| 56.00 (47.00–65.00) | 55.00 (47.00–63.00) | 55.00 (47.00–64.00) | 56.00 (47.00–65.00) | 57.00 (48.00–66.00) | < 0.001 |
| Klotho (median, IQR), pg/ml | 805.20 (657.58–1001.12) | 815.30 (666.98–1002.60) | 803.25 (655.65–1006.35) | 802.85 (654.15–984.85) | 799.20 (651.58–1009.03) | 0.245 |
| eGFR (median, IQR), mL/min/1.73m² | 90.80 (76.29–102.37) | 91.85 (77.83–102.52) | 91.59 (77.53–102.67) | 90.04 (75.25–102.03) | 89.61 (74.72–102.42) | < 0.001 |
| % Sex                   |           |            |            |            |            | < 0.001 |
| male                    | 48.55%    | 61.79%     | 53.22%     | 44.88%     | 34.30%     |         |
| female                  | 51.45%    | 38.21%     | 46.78%     | 55.12%     | 65.70%     |         |
| % Race                  |           |            |            |            |            | < 0.001 |
| Mexican American        | 17.16%    | 18.70%     | 18.23%     | 17.09%     | 14.60%     |         |
| Other Hispanic          | 12.20%    | 11.27%     | 11.79%     | 12.81%     | 12.92%     |         |
| Non-Hispanic White      | 41.16%    | 41.84%     | 42.39%     | 40.15%     | 40.26%     |         |
| Non-Hispanic Black      | 20.19%    | 16.00%     | 18.16%     | 21.23%     | 25.37%     |         |
| Other Race              | 9.30%     | 12.19%     | 9.44%      | 8.71%      | 6.84%      |         |
| % PIR                   |           |            |            |            |            | < 0.001 |
| < 1.3                   | 30.03%    | 23.38%     | 26.44%     | 32.00%     | 38.31%     |         |
| 1.3–3.5                 | 35.98%    | 31.79%     | 35.96%     | 37.51%     | 38.67%     |         |
| > 3.5                   | 33.99%    | 44.83%     | 37.59%     | 30.49%     | 23.01%     |         |
| % BMI                   |           |            |            |            |            | < 0.001 |
| normal (< 25 kg/m²)     | 23.42%    | 26.31%     | 23.58%     | 21.73%     | 22.07%     |         |
| overweight (25–29.9 kg/m²) | 35.28% | 37.10% | 36.25% | 35.14% | 32.62% | |
| obesity (> = 30 kg/m²)  | 41.30%    | 36.59%     | 40.17%     | 43.13%     | 45.31%     |         |
| % Physical activity     |           |            |            |            |            | < 0.001 |
| less than moderate      | 56.26%    | 43.95%     | 55.11%     | 60.50%     | 65.45%     |         |
| moderate                | 8.77%     | 9.50%      | 8.79%      | 8.87%      | 7.91%      |         |
| vigorous                | 34.98%    | 46.53%     | 36.09%     | 30.63%     | 26.65%     |         |
| % Smoothing status      |           |            |            |            |            | < 0.001 |
| Never                   | 52.68%    | 54.51%     | 53.11%     | 51.59%     | 51.50%     |         |
| Former                  | 31.05%    | 34.10%     | 32.50%     | 30.72%     | 26.89%     |         |
| Current                 | 16.27%    | 11.39%     | 14.39%     | 17.69%     | 21.61%     |         |
| % Alcohol intake (gm)   |           |            |            |            |            | < 0.001 |
| none                    | 76.21%    | 68.19%     | 72.40%     | 78.11%     | 86.13%     |         |
| moderate                | 8.06%     | 10.98%     | 9.00%      | 6.55%      | 5.71%      |         |
| heavy                   | 15.73%    | 20.83%     | 18.59%     | 15.34%     | 8.16%      |         |
| CKD                      | No        | 81.74%     | 86.01%     | 82.92%     | 81.21%     | 76.76%  |
|                        | Yes       | 18.26%     | 13.99%     | 17.08%     | 18.79%     | 23.24%  |

Median (IQR) for continuous variables: P value for Mann–Whitney U test
% for Categorical variables: P value for chi-square test

DII quartile ranges: Quartile 1 = -5.18 to -0.16; Quartile 2 = -0.16 to 1.43; Quartile 3 = 1.43 to 2.82; Quartile 4: 2.82 to 5.42
DII Dietary Inflammatory Index, PIR Ratio of family income to poverty, BMI Body Mass Index
* chronic kidney disease (CKD) was defined as albumin-to-creatinine ratio (ACR) above 30 mg/g or estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m².
concentrations among individuals with normal weight ($P$ for trend $= 0.015$), and the $\beta$ was $-25.79$ (95% CI: $-53.91$, $-1.65$) for quartiles 2, 3, and 4, respectively. Similar results were observed in individuals without CKD ($P$ for trend $= 0.002$, $P$ for interaction $= 0.041$). Those in DII quartiles 3 and 4 had a 31.21 and 16.99 pg/ml decrease in serum Klotho level, respectively, compared with those in quartile 1. (95% CI: $-46.95$, $-15.47$; 95% CI: $-33.78$, $-0.21$, respectively). However, the association between DII and serum klotho was not significantly modified by sex or BMI.

### Table 2

| Dietary Inflammatory Index group | Model 1 | Model 2 | Model 3 |
|---------------------------------|---------|---------|---------|
| Continuous                      | -1.59 (-4.40, 1.22) | -4.52 (-7.39, -1.65) | -4.39 (-7.49, -1.28) |
| Quartiles                       |         |         |         |
| Q1                              | 0       | 0       | 0       |
| Q2                              | -9.39 (-24.58, 5.80) | -15.17 (-30.29, -0.04) | -9.75 (-25.53, 6.03) |
| Q3                              | -22.53 (-38.14, -6.92) | -32.62 (-48.30, -16.95) | -25.27 (-41.80, -8.73) |
| Q4                              | 3.11 (-12.77, 19.00) | -12.41 (-28.59, 3.77) | -12.44 (-29.83, 4.95) |
| $P$ for trend                   | 0.626   | 0.001   | 0.036   |

95%CI: 95% Confidence interval
Model 1: no adjust
Model 2: adjusted for age; sex; Race
Model 3: adjusted for age; sex; Race; Ratio of family income to poverty; BMI; alcohol intake; physical activity; smoking; eGFR
DII quartile ranges: Quartile 1 $= -5.18$ to $-0.16$; Quartile 2 $= -0.16$ to $1.43$; Quartile 3 $= 1.43$ to $2.82$; Quartile 4: $2.82$ to $5.42$

### Table 3

| Models                     | serum Klotho concentrations |
|----------------------------|-----------------------------|
|                            | β(95%CI)                   | $P$-value |
| Model I, linear analysis   |                            |           |
| One line slope             | -4.63 (-7.61, -1.65)       | 0.002     |
| Model II, non-linear analysis |                         |           |
| Turning point (K)          | -1.82 (-2.32, -0.80)       |           |
| $<=-1.82$ slope 1          | -33.05 (-52.84, -13.27)    | 0.001     |
| $>-1.82$ slope 2           | -2.19 (-5.61, 1.24)        | 0.211     |
| Slope 2 – Slope 1          | 30.87 (9.63, 52.11)        | 0.004     |
| Predicted at 2.82          | 846.43 (834.62, 858.24)    |           |
| Log likelihood ratio test  | 0.004b                     |           |

Model I, linear analysis
Model II, non-linear analysis

Log likelihood ratio test: $P$-value $< 0.05$ means Model II is significantly different from Model I, which indicates a non-linear relationship

*a* adjusted for age; sex; Race; Ratio of family income to poverty; BMI; alcohol intake; physical activity; smoking; eGFR

*b* indicates that Model II is significantly different from Model I

### Discussion

This study demonstrated there was a dose–response relationship between DII and serum Klotho concentrations; higher DII score was associated with a decreased concentration of serum Klotho on the left side of the turning point; however, the relationship was not significant on the right side of the turning point. Furthermore, stratified analyses showed that the observed association of DII and serum Klotho concentration was stronger and significantly differed by age, BMI, and CKD status.

Klotho is a transmembrane protein with important antiaging functions and anti-inflammatory effects [1, 13]. Recently, Kresovich et al. demonstrated that a lower circulating level of Klotho was associated with all-cause mortality, and the association was stronger in participants with lesser physical activities [8]. This study is the first to use NHANES data and include a general population sample of American adults. This study supported earlier evidence that a low serum level of Klotho is a marker of increased mortality rates. Chronic inflammation plays a major role in decreasing serum Klotho levels [13, 33]. Therefore, an anti-inflammatory diet might increase the serum Klotho level; high Klotho levels may delay aging. Inconsistent with our results, Jurado-Fasoli et al. found a positive association between DII and serum Klotho according to a secondary analysis using the participants of the FIT-AGEING project. However, they only included 73 middle-aged healthy sedentary adults (40–65 years old), and they were unsure whether the study results can be extended to different populations (i.e., younger/older, unhealthy, or physical activity) [24]. In their further study, they observed a negative association...
between Mediterranean diet and serum Klotho level in sedentary middle-aged adults (45–65 years old) [15]; however, traditional Mediterranean diet is associated with a lower incidence of age-related diseases and higher levels of life expectancy [34]. Similar to our results, they found an association between high intake of nuts, an anti-inflammatory food, and high serum Klotho levels [15]. In addition, a proinflammatory dietary pattern was found negatively associated with serum Klotho levels in 139 young adults [25]. In Hsu et al.’s study, resveratrol, which is primarily found in grapes and red wine, induced renal Klotho expression both in vivo and in vitro [35].

In our study, DII was negatively associated with serum Klotho on the left side of the turning point in a general population sample. Aging was also a potential modifier that influenced this negative association. This association was stronger in the older group, possible because natural aging results in a decrease in nephron number, causing the serum Klotho level to decrease; Klotho is an important factor involved in the aging process [36]. In other words, older should pay more attention to dietary habit, reducing red meat and incorporating something green with every meal. Our study also suggested that associations may vary by BMI. Interestingly, the Klotho level appeared to be decreased even more among individuals with normal weight compared with those with overweight and obesity. One possible explanation is that fat tissue is the main source of proinflammatory mediators and that excessive visceral adipose tissue could lead to chronic inflammation, thereby decreasing the serum Klotho level [37]. Therefore, a proinflammatory diet might induce a significant reduction in serum Klotho levels in those with normal weight. However, unlike previous studies, our study found that physical activity did not modify the relationship between DII and serum Klotho concentrations. This relationship was stronger in individuals without CKD than in those with CKD. Klotho is secreted mainly in the distal convoluted tubules, and low Klotho levels are independently associated with kidney function decline [38]. Additionally, serum Klotho levels declined with CKD progression, starting as early as stage 2 CKD [39]. In CKD progression, increasing FGF23 expression and decreasing the active vitamin D levels suppress Klotho expression [40]. Our finding could be explained by DII leading to a more apparent decrease in Klotho concentration in normal participants.

### Table 4 Stratified analyses of association between Dietary Inflammatory Index and serum klotho concentrations (pg/ml) in NHANES 2007–2016

| Variable          | Dietary Inflammatory index group, β (95%CI), Quartiles | P for interaction |
|-------------------|--------------------------------------------------------|------------------|
|                  | Quartile 1     | Quartile 2     | Quartile 3     | Quartile 4     | P for trend |
| Age (year)§       |              |               |               |               | 0.003       |
| 40–56             | 0             | 19.12 (-0.48, 38.73) | -3.88 (-24.88, 17.12) | -0.02 (-22.28, 22.24) | 0.667       |
| 56–80             | 0             | -30.10 (-49.18, -11.02) | -45.72 (-65.20, -26.24) | -32.21 (-52.61, -11.81) | < 0.001     |
| Sex               |              |               |               |               | 0.094       |
| Male              | 0             | -1.89 (-18.68, 14.90) | -33.26 (-51.94, -14.59) | -34.18 (-55.38, -12.98) | < 0.001     |
| Female            | 0             | 0.27 (-22.11, 22.65) | -9.46 (-31.78, 12.87) | -0.13 (-22.56, 22.30) | 0.808       |
| BMI (kg/m²)       |              |               |               |               | 0.015       |
| normal (< 25 kg/m²) | 0          | -25.79 (-53.91, 2.32) | -60.43 (-90.66, -30.21) | -49.89 (-81.59, -18.20) | < 0.001     |
| overweight (25–29.9 kg/m²) | 0    | -4.42 (-27.02, 18.18) | -18.79 (-42.72, 5.14) | -6.37 (-32.15, 19.41) | 0.346       |
| obesity (> = 30 kg/m²) | 0     | 15.76 (-6.21, 37.73) | 1.03 (-21.50, 23.55) | 2.37 (-21.07, 25.81) | 0.901       |
| Physical activity |              |               |               |               | 0.09        |
| Less than moderate | 0           | -13.04 (-32.90, 6.83) | -23.77 (-43.81, -3.72) | -23.83 (-44.40, -3.26) | 0.014       |
| Moderate          | 0             | -30.33 (-77.01, 16.34) | -64.32 (-115.35, -13.29) | 18.67 (-33.41, 70.75) | 0.901       |
| Vigorous          | 0             | 15.11 (-6.26, 36.48) | -12.36 (-35.75, 11.03) | -14.68 (-40.48, 11.12) | 0.187       |
| CKDb             |              |               |               |               | 0.041       |
| No                | 0             | -0.74 (-15.61, 14.13) | -31.21 (-46.95, -15.47) | -16.99 (-33.78, -0.21) | 0.002       |
| Yes               | 0             | -29.05 (-65.83, 7.73) | 3.42 (-33.85, 40.68) | -12.34 (-49.27, 24.58) | 0.923       |

95%CI: 95% Confidence interval
DII quartile ranges: Quartile 1 = -5.18 to -0.16; Quartile 2 = -0.16 to 1.43; Quartile 3 = 1.43 to 2.82; Quartile 4: 2.82 to 5.42
* adjusted for age; sex; Race; Ratio of family income to poverty; BMI; alcohol intake; physical activity; smoking status; eGFR. In each stratification, the model is not adjusted for itself
b chronic kidney disease (CKD) was defined as albumin-to-creatinine ratio (ACR) above 30 mg/g or estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m.²
c the cutoff value was set by median

95%CI: 95% Confidence interval
DII quartile ranges: Quartile 1 = -5.18 to -0.16; Quartile 2 = -0.16 to 1.43; Quartile 3 = 1.43 to 2.82; Quartile 4: 2.82 to 5.42
* adjusted for age; sex; Race; Ratio of family income to poverty; BMI; alcohol intake; physical activity; smoking status; eGFR. In each stratification, the model is not adjusted for itself
b chronic kidney disease (CKD) was defined as albumin-to-creatinine ratio (ACR) above 30 mg/g or estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m.²
c the cutoff value was set by median
Furthermore, our findings are in line with the results of Shivappa et al., who used data from NHANES and reported that a proinflammatory diet was related to a shortened leukocyte telomere length, which is also a marker of biological aging and has been validated to increase all-cause mortality [23]. Currently, studies investigating diet potential and serum Klotho levels in human populations remain limited.

The possible mechanisms for our findings may be through the effect of diet on inflammatory markers. Recent research has identified that both systemic and local inflammmations decrease Klotho expression in the kidneys [13]. Moreno et al. revealed that Klotho is negatively regulated by inflammation in cell culture and in vivo. They found that proinflammatory cytokines, such as TNF-α and TNF-like weak inducer of apoptosis (TWEAK) could downregulate Klotho expression through the canonical activation of the inflammatory transcription factor nuclear factor kappa B (NF-κB) and specifically, a RelA-dependent mechanism [33]. Furthermore, Thurston et al. found that in vitro, TNF could significantly inhibit klotho gene expression secondary to inflammatory bowel disease, which was further potentiated by IFN-γ; in addition, an anti-TNF-α antibody attenuated inflammation and reversed the repression of Klotho expression [41]. Klotho also acts as a coreceptor necessary for FGF-23 function within the kidney [42, 43]. Indeed, FGF23 is a potent negative regulator of Klotho expression. Marsell et al. conducted a microarray analysis of gene expression in the kidneys of FGF23-overexpressing transgenic mice and found that Klotho mRNA was the most significantly decreased transcript [44]. Proinflammatory cytokines, including IL-1, IL-6, and TNF-α, might induce FGF23 expression through NF-κB activation [11, 45, 46]. They could also induce hepcidin secretion in the liver. Abnormally high levels of hepcidin could cause functional iron deficiency. Iron is a negative regulator of FGF23 levels, and iron deficiency increases FGF23 production independent of inflammation, probably by increasing the expression and stability of hypoxia-inducible factor 1α (HIF1α), which binds to hypoxia-responsive elements in the promoter region of Fgf23 and induces its transcription [47]. Therefore, a more proinflammatory diet may elevate the cumulative inflammatory burden and result in the downregulation of klotho gene, thereby decreasing the Klotho level, especially in people who were above 60 years, have less than moderate physical activity, and have no CKD.

This is the first to evaluate the dietary potential of inflammation in relation to serum Klotho concentration using a nationally representative US population. We conducted the threshold effect analysis, and a dose–response relationship was found between DII and serum Klotho concentrations. However, it also has some limitations. First, the cross-sectional nature precluded the establishment of causality. Second, the NHANES database only included participants aged 40–80 years old who were tested for Klotho level measurement; therefore, we do not know whether our results can be applied to younger age groups. Third, dietary information was only evaluated once at a 24-h period, not taking into account the variability of day-to-day diet. Fourth, the distribution of serum Klotho was not normalized. However, considering the small sample size of outliers, the results were stable after the sensitivity analysis, which we excluded participants with Klotho levels > 2500 pg/ml, those with Klotho level > 2000 pg/ml, and those with Klotho level > 2000 pg/ml and DII > 5. Finally, although we adjusted for as many confounders as possible, some unmeasured confounders were still found.

In conclusion, there was a dose–response relationship between DII and serum Klotho concentrations in a nationally representative population of American adults, suggesting that adhering to an anti-inflammatory diet has beneficial effects on aging and health by increasing the serum Klotho concentration. Future human research is warranted to determine the causal relationship between DII and serum Klotho concentration.

Abbreviations
Klotho: Alpha-Klotho; FGF23: Fibroblast growth factor 23; TNF-α: Tumor necrosis factor-α; IFN-γ: Interferon γ; IL-6: Interleukin-6; DII: Dietary Inflammatory Index; NHANES: National Health and Nutrition Examination Survey; BMI: Body mass index; eGFR: Glomerular filtration rate; MVPA: Moderate-to-vigorous physical activity; CKD: Chronic kidney disease; SD: Standard deviations; IQR: Interquartile range; NF-κB: Factor nuclear factor kappa B.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12877-022-03228-8.

Additional file 1: Supplementary figure 1. Participants selection flowchart.
Additional file 2: Supplementary figure 2. Association between Dietary Inflammatory index and serum klotho concentrations among adults in NHANES 2007-2016.
Additional file 3: Supplementary Material. The method of the calculation of Dietary Inflammatory Index.

Acknowledgements
The authors thank Dr Chi Chen, Changzhong Chen, and Xing-Lin Chen for providing statistical methodology consultation.

Authors’ contributions
CCZ, ZLZ and JKL contributed equally as first authors of this manuscript. SQ and BRD are responsible for the conception and design of the study. SQ, JWG, LHD, KJ, and XNZ interpreted the analysis. CCZ, JKL, KJ, and LHD were responsible for the acquisition of data. CCZ, ZLZ, and JKL wrote the first draft of the manuscript, interpreted the data and wrote the final version. All authors critically reviewed the article for important intellectual content and approved the final version. The authors read and approved the final manuscript.
Funding
This work was supported by the National Natural Science Foundation of China (Grant No.81902057, 81974098, 819732158), Programs from Science and Technology Department of Sichuan Province (2021YB0462), the project of Health Commission of Sichuan Province (2020PY062, 20PJ039), Post-
doctoral Science Research Foundation of Sichuan University (2020SCU12041), Post-Doctor Research Project, West China Hospital, Sichuan University (2018XKH084, 2019XKH092).

Availability of data and materials
The data sets generated and/or analyzed during the current study are avail-
able from the NHANES repository, https://www.cdc.gov/nchs/nhanes/.

Declarations

Ethics approval and consent to participate
The survey was performed by the National Center for Health Statistics (NCHS) and approved by the NCHS Institutional Review Board (IRB). All informed consents had been obtained from the eligible subjects before initiating data collection and NHANES health examinations. (https://www.cdc.gov/nchs/ nhanes/erbd18.htm).

Consent for publication
Not applicable.

Competing interests
All authors in the study declare no conflicts of interest.

Author details
1. Department of Urology, Institute of Urology and National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, No. 37, Guoxue Lane, Chengdu 610041, Sichuan Province, People’s Republic of China.
2. National Clinical Research Center of Geriatrics, The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, People’s Republic of China.
3. Department of Gerontology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People’s Republic of China.
4. Department of Nephrology, and National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, No. 37, Chengdu 610041, Sichuan, People’s Republic of China.

Received: 2 December 2021   Accepted: 10 June 2022

Published online: 27 June 2022

References
1. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Klotho and the Treatment of Human Malignancies. Cancers. 2020;12(2):281.
2. Jurado-Fasoli L, Castillo MJ, Amaro-Gahete FJ. Dietary Inflammatory Index and S-Klotho Plasma Levels in Middle-Aged Adults. Nutrients. 2016;8(10):683–92.
3. Wang X, Zhang J, Ma Y, Liao A, Hebert JR, et al. The Dietary Inflammatory Index Is Associated with Prostate Cancer Risk in French Middle-Aged Adults in a Prospective Study. J Nutr. 2016;146(4):785–91.
4. Sack J, Katsambas A, Kuehnert M, Schmitt B, Madsen CM, et al. Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun. 2010;398(3):513–8.
5. Ogata N, Matsumura Y, Shiraki M, Kawano K, Koshizuka Y, Hosoi T, et al. Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women. Bone. 2002;31(1):37–42.
6. Kreisovich JR, Bulka CM. Low serum Klotho associated with all-cause mortality among a nationally representative sample of American adults. J Gerontol A Biol Sci Med Sci. 2022;77(3):452–6.
7. Sacks D, Baxter B, Campbell BVC, Carpenter JS, Cognard C, Dippel D, et al. Multisociety Consensus Qualuty Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612–32.
8. Shiroma N, Steck SE, Hussey JR, Ma Y, Hebert JR. Inflammatory potential of diet and all-cause, cardiovascular, and cancer mortality in National Health and Nutrition Examination Survey III Study. Eur J Nutr. 2017;56(2):683–92.
9. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651.
10. Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol. 2013;180:47–63.
11. Izquierdo MC, Perez-Gomez MV, Sanchez-Nino MD, Sanz AB, Ruiz-Andres O, Poveda J, et al. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant. 2012;27(Suppl 4):ix6-10.
12. Chiukhi A, Barchowsky A, Sahu A, Shinde SN, Pius A, Clemens ZJ, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281(10):6120–3.
13. Ogata N, Matsumura Y, Shiraki M, Kawano K, Koshizuka Y, Hosoi T, et al. Klotho and the Treatment of Human Malignancies. Cancers. 2020;12(2):281.
14. Ogata N, Steck SE, Hurley TG, Hussey JR, Hebert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutr. 2014;17(8):1689–96.
15. Ogata N, Dmochowski RR, Kim S, Hullar JM, Zhang J, Ma Y, et al. The dietary inflammatory index (DII) and telomere length and C-reactive protein from the PREMID (PREvention con Dieta MEDiterranea) trial. Br J Nutr. 2015;113(6):984–95.
16. Shivappa N, Steck SE, Hurley TG, Ortigia A, Drayton R, et al. Construct Validation of the Dietary Inflammatory Index among African Americans. J Nutr Health Aging. 2017;21(5):487–91.
17. Tabung FK, Steck SE, Zhang J, Ma Y, Liese AD, Aguilera I, et al. Construct validation of the dietary inflammatory index among postmenopausal women. Ann Epidemiol. 2015;25(6):398–405.
18. Jurado-Fasoli L, Amaro-Gahete FJ, De-la-OA, Martinez-Telles B, Ruiz JR, Gutierrez A, et al. Adherence to the Mediterranean diet, dietary factors, and S-Klotho plasma levels in sedentary middle-aged adults. Exp Gerontol. 2019;119:25–32.
19. Shivappa N, Steck SE, Zhang J, Ma Y, Liese AD, Aguilera I, et al. Construction of the Dietary Inflammatory Index among African Americans. J Nutr Health Aging. 2017;21(5):487–91.
20. Ruiz-Canela M, Zazpe I, Shivappa N, Hebert JR, Sanchez-Tainta A, Corella D, et al. Dietary inflammatory index and anthropometric measures of obesity in a population sample at high cardiovascular risk from the PREDIMED (PREvención con Dieta MEDiterránea) trial. Br J Nutr. 2015;113(6):984–95.
21. Graffouillère L, Deschasaux M, Mariotti F, Shivappa N, Hebert JR, et al. The Dietary Inflammatory Index Is Associated with Prostate Cancer Risk in French Middle-Aged Adults in a Prospective Study. J Nutr. 2016;146(4):785–91.
22. Neufcourt L, Assmann KE, Fezeu LK, Touvier M, Graffouillère L, Shivappa N, et al. Prospective Association Between the Dietary Inflammatory Index and Cardiovascular Diseases in the SuPplémentation en Vitamines et Minéraux AntioXydants (SU.VI.MAX) Cohort. J Am Heart Assoc. 2016;5(3):e002735.
23. Tabung FK, Steck SE, Zhang J, Ma Y, Liese AD, Aguilera I, et al. Prospective Association Between the Dietary Inflammatory Index and Cardiovascular Diseases in the Supplementation en Vitamines et Minéraux Antioxydants (SU.VI.MAX) Cohort. J Am Heart Assoc. 2016;5(3):e002735.
24. Curto AR, Shivappa N, Hebert JR. Dietary Inflammatory Index Is Associated with Prostate Cancer Risk in French Middle-Aged Adults in a Prospective Study. J Nutr. 2016;146(4):785–91.
25. Jurado-Fasoli L, Amaro-Gahete FJ, Arias-Telles MJ, Gil A, Labayen I, Ruiz JR, et al. Dietary inflammatory index (DII) and telomere length and C-reactive protein from the National Health and Nutrition Examination Survey-1999-2002. Mol Nutr Food Res. 2017;61(4):10.1002/mnfr.201600630.
26. Jurado-Fasoli L, Castillo MJ, Amaro-Gahete FJ, Neufcourt L, Shivappa N, Hebert JR, et al. The Dietary Inflammatory Index Is Associated with Prostate Cancer Risk in French Middle-Aged Adults in a Prospective Study. J Nutr. 2016;146(4):785–91.
27. Shivappa N, Steck SE, Hurley TG, Hussey JR, Hebert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutr. 2014;17(8):1689–96.
28. Shivappa N, Steck SE, Hurley TG, Hussey JR, Hebert JR. Inflammatory potential of diet and all-cause mortality among a nationally representative sample of American adults. J Gerontol A Biol Sci Med Sci. 2022;77(3):452–6.
29. Sakai Y, Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al. Klotho and the Treatment of Human Malignancies. Cancers. 2020;2(16):1665.
30. Sack J, Katsambas A, Kuehnert M, Schmitt B, Madsen CM, et al. Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun. 2010;398(3):513–8.
28. Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al. Trends in Prevalence of Chronic Kidney Disease in the United States. Ann Intern Med. 2016;165(7):473–81.

29. Jurado-Fasoli L, Amaro-Gahete FJ, De-la OA, Gutiérrez A, Castillo MJ. Alcohol consumption and S-Klotho plasma levels in sedentary healthy middle-aged adults: A cross sectional study. Drug Alcohol Depend. 2019;194:107–11.

30. Grabovac I, Cao C, Haider S, Stefanac S, Jackson SE, Swami V, et al. Associations Among Physical Activity, Sedentary Behavior, and Weight Status With Sexuality Outcomes: Analyses from National Health and Nutrition Examination Survey. J Sex Med. 2020;17(1):60–8.

31. Bao W, Liu B, Rong S, Dai SY, Trasande L, Lehmler HJ. Association Between Bisphenol A Exposure and Risk of All-Cause and Cause-Specific Mortality in US Adults. JAMA Netw Open. 2020;3(8):e2011620.

32. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

33. Moreno JA, Izquierdo MC, Sanchez-Niño MD, Suárez-Alvarez B, Lopez-Larrera C, Jakubowski A, et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol. 2011;22(7):1315–25.

34. Ross SM. The traditional Mediterranean diet: an ancient prescription for health and longevity. Holist Nurs Pract. 2015;29(3):174–7.

35. HSU SC, Huang SM, Chen A, Sun CY, Lin SH, Chen JS, et al. Resveratrol increases anti-aging Klotho gene expression via the activating transcription factor 3/c-Jun complex-mediated signaling pathway. Int J Biochem Cell Biol. 2014;53:361–71.

36. Denic A, Lieske JC, Chakkeria HA, Poggio ED, Alexander MP, Singh P, et al. The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging. J Am Soc Nephrol. 2017;28(1):313–20.

37. Calder PC, Aihluwalia N, Brouns F, Bueter T, Clement K, Cunningham K, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr. 2011;106(Suppl 3):S5-S78.

38. Drew DA, Katz R, Kritchkevsky S, Ix J, Shlipak M, Gutierrez OM, et al. Association between Soluble Klotho and Change in Kidney Function: The Health Aging and Body Composition Study. J Am Soc Nephrol. 2017;28(6):1839–68.

39. Barker SL, Pastor J, Carranza D, Quinhoes H, Griffith C, Goetz R, et al. The demonstration of αKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrol Dial Transplant. 2015;30(2):223–33.

40. Kuro OM. The Klotho proteins in health and disease. Nat Rev Nephrol. 2019;15(1):27–44.

41. Thurston RD, Larmonier CB, Majewski PM, Ramalingam R, Midura-Kiela M, Laubitz D, et al. Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. Gut. 2010;59(4):538–43, e1–e2.

42. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004;565(1–3):143–7.

43. Kato Y, Arakawa E, Kinoshita S, Shirai A, Furuya A, Yamano K, et al. Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys. Biochem Biophys Res Commun. 2000;267(2):597–602.

44. Marsell R, Krajisnik T, Grönsson H, Olsson C, Ljunggren O, Larsson TE, et al. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transplant. 2008;23(3):827–33.

45. Zhang B, Umbach AT, Chen H, Yan J, Fakhri H, Fajol A, et al. Up-regulation of FGF23 release by aldosterone. Biochem Biophys Res Commun. 2016;470(2):384–90.

46. de Seigneux S, Martin PY. Phosphate and FGF23 in the renoprotective benefit of RAAS inhibition. Pharmacol Res. 2016;106:87–91.

47. David V, Francis C, Babitt JI. Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol. 2017;312(1):F1-F8.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Ready to submit your research?** Choose BMC and benefit from:

- Fast, convenient online submission
- Thorough peer review by experienced researchers in your field
- Rapid publication on acceptance
- Support for research data, including large and complex data types
- Gold Open Access which fosters wider collaboration and increased citations
- Maximum visibility for your research: over 100M website views per year

Learn more biomedcentral.com/submissions

---

At BMC, research is always in progress.